fe-BUX-o-stat
REMS
Chronic management of hyperuricemia in patients with gout who have an inadequate response to a maximally titrated dose of allopurinol, who are intolerant to allopurinol, or in whom allopurinol is not an appropriate treatment option.
Contraindicated in:
Use Cautiously in:
Cardiovascular disease (↑ risk of cardiovascular death compared to allopurinol) (consider using low-dose aspirin when using febuxostat in these patients)
;Derm: DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS (DRESS), rash, STEVENS-JOHNSON SYNDROME, TOXIC EPIDERMAL NECROLYSIS
GI: ↑liver enzymes, nausea
MS: arthralgia, gout flare
Drug-drug:
Should only be used in patients who have an inadequate response to a maximally titrated dose of allopurinol, who are intolerant to allopurinol, or for whom treatment with allopurinol is not advisable.
Renal Impairment
Therapeutic Classification: antigout agents
Pharmacologic Classification: xanthine oxidase inhibitors
Absorption: 49% absorbed following oral administration.
Distribution: Widely distributed to tissues.
Protein Binding: 99.2%.
Half-Life: 5–8 hr.
(plasma concentrations)
| ROUTE | ONSET | PEAK | DURATION |
|---|---|---|---|
| PO | rapid | 1–1.5 hr* | 24 hr |
*Maximum lowering of uric acid may take 2 wk.
NDC Code